// App-Quantinova.ai

: Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST

Researchers

Presenter

  • Sally Wenzel

Principal Investigators

  • Ian D. Pavord

  • Klaus F. Rabe

  • Alberto Papi

  • J. Mark Fitzgerald

  • Alexandre Jagerschmidt

  • William Brian

  • Qungming Dong

  • Brian N. Swanson

  • Jennifer D. Hamilton

  • Nikhil Amin

  • Gianluca Pirozzi

  • Marcella Ruddy

  • Bolanle Akinlade

  • Neil M.H. Graham

  • Ariel Teper

Medical Centers

  • University of Pittsburgh, Heart and Vascular Institute, Pittsburgh, United States of America

  • Oxford Eye Hospital, University of Oxford, Oxford, United Kingdom

  • LungenClinic Großhansdorf and Christian Albrechts University Kiel, German Center for Lung Research (DZL), Kiel, Germany

  • University of Ferrara, Ferrara, Italy

  • Sanofi, Chilly-Mazarin, France

  • Sanofi US, Bridgewater, United States of America

  • Regeneron Pharmaceuticals - Tarrytown - United States of America

Locations

  • United States

  • United Kingdom

  • Germany

  • Italy

  • Canada

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • C-C Motif Chemokine Ligand 17

  • Immunoglobulin E

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01854047

  • NCT02414854

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved